News & Media

Nov 07, 2023

Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023

- At 6 months patients treated with AR882 75 mg showed significantly higher response rate of at least one complete target tophi dissolution - On track to initiate pivotal phase 3 program in early 2024 —

Read More
Oct 17, 2023

Arthrosi Announces Multiple Presentations at the American College of Rheumatology (ACR) Convergence 2023

Arthrosi today announced the acceptance of three poster presentations and one late breaking oral presentation at the American College of Rheumatology (ACR) Convergence 2023 meeting, being held in San Diego, CA on November 10-15, 2023.

Read More
Aug 18, 2023

Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study

Arthrosi announced they have received written response from the U.S. Food and Drug Administration (FDA) related to their End-of-Phase 2 briefing package for AR882, its lead drug candidate for gout treatment. AR882 is a highly potent, selective, and once daily dosing next-gen URAT1 inhibitor. The feedback from the FDA supports Arthrosi progressing with its planned Phase 3 clinical program.

Read More
Jul 11, 2023

Arthrosi Secures $75m In Series D Financing

Arthrosi announced the successful securing of $75 million in Series D financing.

Read More
Jan 05, 2023

Arthrosi Announces Positive Topline Results For AR882 Phase 2B Study

Arthrosi announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.

Read More
Aug 23, 2022

Arthrosi Completes AR882 Phase 2b Study Enrollment

Arthrosi announced the completion of enrollment for its global Phase 2b clinical study of AR882 for the treatment of chronic gout. The study, which exceeded the initial target enrollment of 120 patients, is designed to evaluate the safety and efficacy of AR882, an effective and selective uricosuric agent, in chronic gout patients who meet ACR/EULAR gout classification.

Read More
Aug 09, 2022

Arthrosi Completes AR882 Renal Impairment Study

Arthrosi announced the completion of its renal impairment study utilizing the lead compound, AR882. AR882 is a potent and selective uricosuric agent, which has shown effectiveness lowering serum urate in patients with normal renal function, and in patients with mild to severe renal impairment.

Read More
Feb 22, 2022

Arthrosi Welcomes New Chief Financial Officer

Arthrosi announced the appointment of Philip Moody as its Chief Financial Officer, who brings more than 25 years of experience and a track record of success working in private and public biotech companies.

Read More
Dec 14, 2021

Arthrosi Therapeutics, Inc. Announces Patient Enrollment in Global Phase 2b Study of AR882

Arthrosi announced today patient enrollment in a global phase 2b study of AR882, its novel drug candidate. AR882 is a new uricosuric agent in clinical development for the management of hyperuricemia in patients with gout, including patients with chronic, refractory tophaceous gout.

Read More
Nov 02, 2021

Arthrosi Presents AR882 Posters at ACR 2021

Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced results from its renal impairment studies and human AME study.

Read More